Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. / Johansson, Pär I; Ostrowski, Sisse R.

I: Drug Design, Development and Therapy, Bind 4, 01.01.2010, s. 107-16.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Johansson, PI & Ostrowski, SR 2010, 'Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders', Drug Design, Development and Therapy, bind 4, s. 107-16.

APA

Johansson, P. I., & Ostrowski, S. R. (2010). Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. Drug Design, Development and Therapy, 4, 107-16.

Vancouver

Johansson PI, Ostrowski SR. Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. Drug Design, Development and Therapy. 2010 jan. 1;4:107-16.

Author

Johansson, Pär I ; Ostrowski, Sisse R. / Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders. I: Drug Design, Development and Therapy. 2010 ; Bind 4. s. 107-16.

Bibtex

@article{b3ddaee0f5914f62a7917554109582c3,
title = "Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders",
abstract = "Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.",
author = "Johansson, {P{\"a}r I} and Ostrowski, {Sisse R}",
year = "2010",
month = jan,
day = "1",
language = "English",
volume = "4",
pages = "107--16",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

AU - Johansson, Pär I

AU - Ostrowski, Sisse R

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

AB - Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.

M3 - Journal article

VL - 4

SP - 107

EP - 116

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -

ID: 34110656